On Apr. 1, 2022, the Fred Hutchinson Cancer Research Center and Seattle Cancer Care Alliance (SCCA) announced a…
On Apr. 1, 2022, Merck and Ridgeback Biotherapeutics announced that data evaluating LAGEVRIO(molnupiravir), an investigational oral antiviral COVID-19…
On Mar. 31, 2022, researchers in Brazil reported that a study of COVID-19 patients at 12 clinics that…
On Mar. 31, 2022, Sorrento Therapeutics announced that the FDA had given clearance to commence the Phase 3…
On Mar. 30, 2022, Lucira Health announced that preliminary clinical trial results for its candidate COVID-19 & Flu…
On Mar. 29, 2022, Pfizer and BioNTech announced that the U.S. Food and Drug Administration (FDA) had expanded…
On Mar. 22, 2022, Pfizer announced an agreement with UNICEF to supply up to 4 million treatment courses…
On Mar. 21, 2022, Twist Bioscience announced the launch of specific synthetic RNA positive controls for SARS-CoV-2 encapsulated…
On Mar. 21, 2022, in support of the Cancer Moonshot goal of fostering data sharing in cancer research,…
On Mar. 18, 2002, Johnson & Johnson announced an agreement to acquire all of the assets of Tibotec-Virco…
On Mar. 17, 2022, the National Institutes of Health announced that nearly 100,000 highly diverse whole genome sequences…
On Mar. 17, 2022, Soligenix announced the results of a booster vaccination study using CiVax (heat stable COVID-19…
On Mar. 10, 2022, Cocrystal Pharma announced dosing of the first subjects in a Phase 1 clinical trial…
On Mar. 10, 2022, schools with mandatory masking during the Delta surge had approximately 72% fewer cases of…
On Mar. 10, 2022, the Institute for Health Metrics and Evaluation (IHME) reported that more than three times…
On Mar. 9, 2022, Pfizer announced that it had initiated a Phase 2/3 study, EPIC-PEDS (Evaluation of ProteaseInhibition…
On Mar. 2, 2022, the U.S. Department of Agriculture’s Animal and Plant Health Inspection Service (APHIS) confirmed the…
On Mar. 2, 2022, Sorrento Therapeutics announced that it had received clearance from the FDA for its investigational…
On Feb. 28, 2022, the Patent and Trial Appeal Board of the U.S. Patent and Trademark Office (USPTO)…
On Feb. 22, 2022, Sorrento Therapeutics announced that additional preclinical results demonstrate broad spectrum COVISHIELD (STI-9167) neutralizing activity…
On Feb. 1, 2022, University of Virginia Cancer Center announced it had been awarded a Comprehensive Cancer Center…
On Feb. 17, 2022, after studying blood samples from 244 patients hospitalized for COVID-19, a group of researchers,…
On Feb. 17, 2022, Resverlogix announced that the first Brazilian site had been initiated for its Phase 2b…
On Feb. 15, 2022, a woman with HIV who received a cord blood stem cell transplant to treat…
On Feb. 12, 2022, China’s medical products regulator announced that it had given conditional approval for Pfizer’s COVID-19…
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
On Feb. 11, 2022, Gilead Sciences announced new data from an interim analysis of its ongoing, Phase 2/3…
On Feb. 8, 2022, Merck and Ridgeback Biotherapeutics announced that a total of 3.1 million courses of molnupiravir,…
On Feb. 2, 2022, NIAID scientists announced the new Pandemic Preparedness Plan aimed to support critical basic and…
On Feb. 2, 2022, a new analysis of the first two patients treated in a clinical trial with…